News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merrimack Pharmaceuticals Inc. Lung Cancer Drug Fails in One Mid-Stage Trial Group



4/4/2013 9:03:12 AM

Merrimack Pharmaceuticals Inc said one of three patient groups in a mid-stage trial of its experimental lung cancer drug failed to meet the main goal of improving survival rates after four months of treatment without the disease worsening. The company's shares fell 7 percent in premarket trade. The group was administered the drug, MM-121, in combination with erlotinib, an approved cancer treatment, for non-small cell lung cancer. Erlotinib is marketed as Tarceva by Swiss drugmaker Roche Holding AG.

Read at Reuters
Read at Fox News


comments powered by Disqus
Reuters
Fox News
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES